Next report date
Report period
Q1 2024
EPS estimate
−0.19USD
Revenue estimate
—
−1.1450USD
−18.35 MUSD
16.78 M
About Theriva Biologics, Inc.
Sector
CEO
Steven A. Shallcross
Headquarters
Rockville
Website
Employees (FY)
22
Founded
2001
FIGI
BBG000BV6QX8
Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of TOVX is 0.4100 USD — it has increased by 11.22% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange Theriva Biologics, Inc. stocks are traded under the ticker TOVX.
Theriva Biologics, Inc. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
TOVX stock is 26.13% volatile and has beta coefficient of 1.55. Check out the list of the most volatile stocks — is Theriva Biologics, Inc. there?
TOVX earnings for the last quarter are −0.19 USD per share, whereas the estimation was −0.42 USD resulting in a 54.76% surprise. The estimated earnings for the next quarter are −0.41 USD per share. See more details about Theriva Biologics, Inc. earnings.
Yes, you can track Theriva Biologics, Inc. financials in yearly and quarterly reports right on TradingView.
TOVX stock has fallen by 8.90% compared to the previous week, the month change is a 18.82% fall, over the last year Theriva Biologics, Inc. has showed a 40.99% decrease.
TOVX net income for the last quarter is −5.49 M USD, while the quarter before that showed −3.30 M USD of net income which accounts for −66.06% change. Track more Theriva Biologics, Inc. financial stats to get the full picture.
Today Theriva Biologics, Inc. has the market capitalization of 7.03 M, it has decreased by 4.60% over the last week.
No, TOVX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, TOVX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Theriva Biologics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 22.00 employees. See our rating of the largest employees — is Theriva Biologics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Theriva Biologics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Theriva Biologics, Inc. stock shows the sell signal. See more of Theriva Biologics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Theriva Biologics, Inc. future price: according to them, TOVX price has a max estimate of 2.00 USD and a min estimate of 2.00 USD. Read a more detailed Theriva Biologics, Inc. forecast: see what analysts think of Theriva Biologics, Inc. and suggest that you do with its stocks.